Physiological and Laboratory Markers of Drug Effect

Principles of Clinical Pharmacology, Third Edition

Volumn , Issue , 2012, Pages 309-325

  Woodcock, Janet ^a   Atkinson, Arthur J ^b   Rolan, Paul ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870283851     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385471-1.00018-0     Document Type: Chapter

References (86)

1. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69 89-95.
2. R. Frank and R. Hargreaves (2003) Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2 566-580.
3. J.A. Wagner (2002) Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18 41-46.
4. J.A. Wagner (2008) Strategic approach to fit-for-purpose biomarkers in drug development. Ann Rev Pharmacol Toxicol 48 631-651.
5. J. Woodcock (2010) Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther 88 765-773.
6. Institute of Medicine Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease (2010) C.M. Michael, J.R. Ball (Eds) Evaluation of biomarkers and surrogate endpoints in chronic disease Washington, DC: The National Academies Press
7. P. Kohl, E.J. Crampin, T.A. Quinn and D. Noble (2010) Systems biology: An approach. Clin Pharmacol Ther 88 25-33.
8. CDER CVM (2001) Bioanalytical method validation. Rockville, MD: FDA (Internet at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf ) Guidance for Industry
9. D. Mildvan, A. Landay, V. De Gruttola, S.G. Machado and J. Kagan (1997) An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 24 764-774.
10. A. Di Leo, M. Dowsett, B. Horten and F. Penault-Liorca (2002) Current status of HER2 testing. Oncology 63(Suppl. 1), 25-32.
11. M. Elizabeth, H. Hammond, P. Barker, S. Taube and S. Gutman (2003) Standard reference material for HER2 testing: Report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol 11 103-106.
12. A.C. Wolff, M. Elizabeth, H. Hammond, J.N. Schwartz, K.L. Hagerty, D.C. Aldred, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 118-145.
13. A.R. Padhani, G. Liu, D. Mu-Koh, T.L. Chenevert, H.C. Thoeny, T. Takahara, et al. (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia 11 1102-1125.
14. A.K.P. Shanbhogue, A.B. Karnand and S.R. Prasad (2010) Tumor response evaluation in oncology: Current update. J Comput Assist Tomogr 34 479-484.
15. F.M. Goodsaid and F.W. Frueh (2008) Mattes. Strategic paths for biomarker qualification. Toxicology 245 219-223.
16. CDER (2010) Qualification process for drug development tools. Draft Guidance for Industry. Silver Spring, MD: FDA www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM230597.pdf ) (Internet at
17. F.M. Goodsaid and D.L. Mendrick (2010) Translational medicine and the value of biomarker qualification. Sci Transl Med 2 47. ps44
18. F.M. Goodsaid, M. Blank, F. Dieterle, P. Harlow, E. Hausner, F. Sistare, et al. (2009) Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther 86 490-496.
19. R. Temple (1999) Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 790-795.
20. L.J. Lesko and A.J. Atkinson Jr. (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making. Ann Rev Pharmacol 41 347-366.
21. R.J. Temple (1995) A regulatory authority’s opinion about surrogate endpoints. W.S. Nimmo, G.T. Tucker (Eds) Clinical measurement in drug evaluation New York, NY: J Wiley
22. T.R. Fleming and D.L. DeMets (1996) Surrogate endpoints in clinical trials: Are we being misled? Ann Intern Med 125 605-613.
23. R. Temple (1999) Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282 790-795.
24. D.S. Echt, P.R. Liebson, B. Mitchell, R.W. Peters, D. Obias-Manno, A.H. Barker, et al., CAST Investigators (1991) Mortality and morbidity of patients receiving encainide, flecainide or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 781-788.
25. R.L. Prentice (1989) Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8 431-440.
26. A. Shatzkin, L.S. Freedman, M.H. Schiffman and S.M. Dawsey (1990) Validation of intermediate endpoints in cancer research. J Natl Cancer Inst 82 1746-1752.
27. L.S. Freedman and B.I. Graubard (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11 167-178.
28. D.Y. Lin, T.R. Fleming and V. De Gruttola (1997) Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16 1515-1527.
29. V.G. De Gruttola, P. Clax, D.L. DeMets, G.J. Downing, S.S. Ellenberg, L. Friedman, et al. (2001) Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials 22 485-502.
30. Code of Federal Regulations. Washington, DC: US Government Printing Office Title 21, Vol. 5, Parts 300–499
31. HIV Surrogate Marker Collaborative Group (2000) Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: A meta-analysis. AISA Res Hum Retroviruses 16 1123-1132.
32. CDER (2002) Antiretroviral drugs using plasma HIV RNA measurements – clinical considerations for accelerated and traditional approval. Guidance for Industry. Rockville, MD: FDA www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf ) (Internet at
33. C.D. Lathia, D. Amakye, C. Girman, S. Madani, J. Mayne, P. MacCarthy, et al. (2009) The value, qualification and regulatory use of surrogate endpoints in drug development. Clin Pharmacol Ther 86 32-43.
34. CDRH CDER CBER (2011) In vitro companion diagnostic devices. Draft Guidance for Industry, Rockville, MD: FDA www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf ) (Internet at
35. F.H. Messerli and G.S. Panjrath (2009) The J-curve between blood pressure and coronary artery disease or essential hypertension. J Am Coll Cardiol 54 1827-1834.
36. W.B. Kannel (2009) Hypertension: Reflections on risks and prognostication. Med Clin North Am 93 541-556.
37. R.W.R. Russell (1975) How does blood-pressure cause stroke? Lancet ii 1283-1285.
38. M.R. Law, J.K. Morris and N.J. Wald (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 32 729-741.
39. W.N. Kernan, C.M. Viscoli, L.M. Brass, J.P. Broderick, T. Brott, E. Feldmann, et al. (2000) Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343 1826-1832.
40. G.A. Fleming (2000) The FDA, regulation, and the risk of stroke. N Engl J Med 343 1886.
41. W. Philip, T. James, I.D. Caterson, W. Coutinho, N. Finer, L.F. Van Gaal, et al., for the SCOUT Investigators (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363 905-917.
42. J.W. Lee and M. Hall (2009) Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol. Biomed Life Sci 877 1259-1271.
43. K. Blennow (2010) Biomarkers in Alzheimer’s disease drug development. Nat Med 16 1218-1222.
44. C.C. Rowe, U. Ackerman, W. Browne, R. Mulligan, K.L. Pike, G. O’Keefe, et al. (2008) Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 7 129-135.
45. C.J. Bench, G.W. Price, A.A. Lammertsma, J.C. Cremer, S.K. Luthra, D. Turton, et al. (1991) Measurement of human cerebral monamine oxidase type B (MAO-B) activity with positron emission tomography (PET): A dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 40 169-173.
46. P. Rolan, M. Danhof, D. Stanski and C. Peck (2007) Current issues relating to drug safety especially with regard to the use of biomarkers: A meeting report and progress update. Eur J Pharm Sci 30 107-113.
47. E. Krynetski and W.E. Evans (2003) Drug methylation in cancer therapy: Lessons from the TPMT polymorphism. Oncogene 22 7403-7413.
48. W.-H. Chung, S.-I. Hung, H.-S. Hong, M.-S. Hsih, L.-C. Yang, H.-C. Ho, et al. (2004) A marker for Stevens-Johnson syndrome. Nature 428 486.
49. CDER CBER (2005) E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Guidance for Industry. Rockville, MD: FDA www.fda.go/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf ) (Internet at
50. C. Graff, J.J. Struijk, J. Matz, J.K. Kanters, M.P. Andersen, J. Nielsen, et al. (2010) Covariate analysis of QTc and T-wave morphology: New possibilities in the evaluation of drugs that affect cardiac repolarization. Clin Pharmacol Ther 88 88-94.
51. B. Rodriguez, K. Burrage, D. Gavaghan, V. Grau, P. Kohl and D. Noble (2010) The systems biology approach to drug development: Application to toxicity assessment of cardiac drugs. Clin Pharmacol Ther 88 130-134.
52. G. Davey Smith and J. Pekkanen (1992) Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304 431-434.
53. J.C. LaRosa, D. Hunninghake, M.H. Criqui, G.S. Getz, A.M. Gotto Jr., S.M. Grundy, et al. (1990) The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 81 1721-1733.
54. R.W. Wissler and D. Vesselinovitch (1990) Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animal models. Am J Cardiol 65 33F-40F.
55. M.J.T.M. Mol and D.W. Erkelens (1986) Gevers Leuven JA, Schouten JA, Stalenhoef AFH. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet ii 936-939.
56. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 1383-1389.
57. T.R. Pedersen, A.G. Olsson, O. Færgeman, J. Kjekshus, H. Wedel, K. Berg, et al., for the Scandinavian Simvastatin Survival Study Group (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation 97 1453-1460.
58. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, et al. (2004) Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 720-732.
59. C.J. Vaughan, M.B. Murphy and B.M. Buckley (1996) Statins do more than just lower cholesterol. Lancet 348 1079-1082.
60. West of Scotland Coronary Prevention Study Group (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 1440-1445.
61. D.L. Buckley, R. Fu, M. Freeman, K. Rogers and M. Helfand (2009) C-reactive protein as a risk factor for coronary heart disease: A systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 151 483-496.
62. E. Corrado, M. Rizzo, G. Coppola, K. Fattouch, G. Novo, I. Marturana, et al. (2010) An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 17 1-11.
63. A. Blum and R. Shamburek (2009) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 203 325-330.
64. J. Reinoehl, D. Frankovich, C. Machado, R. Kawasaki, J.J. Baga, L.A. Pires, et al. (1996) Probucol-associated tachyarrhythmic events and QT prolongation: Importance of gender. Am Heart J 131 1184-1191.
65. M.G. Silverman, M.J. Blaha and R.S. Blumenthal (2011) Adjunctive lipid lowering therapy in the era of surrogate endpoints. Cardiol Rev 19 17-22.
66. J.J.P. Kastelein, F. Akdim, E.S.G. Stroes, A.H. Zwinderman, M.L. Bots, A.F.H. Stalenhoef, et al., ENHANCE Investigators (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 1431-1443.
67. M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall and M. Sitzer (2007) Prediction of cardiovascular events with carotid intima–media thickness – a systemic review and meta-analysis. Circulation 115 459-467.
68. M.W. Lorenz, H. Bickel, M.L. Bots, M.M.B. Breteler, A.L. Catapano, M. Desvarieux, et al. (2010) PROG-IMT Study Group. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. Am Heart J 159 730-736.
69. P. Rolan (1997) The contribution of clinical pharmacology surrogates and models to drug development – a critical appraisal. Br J Clin Pharmacol 44 219-225.
70. D.R. Abernethy, J. Woodcock and L.J. Lesko (2011) Pharmacological mechanism-based drug safety assessment and prediction. Clin Pharm Ther 89 793-797.
71. L.J. Lesko and J. Woodcock (2004) Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective. Nat Rev Drug Discov 3 763-769.
72. O.N. Ikediobi, J. Shin, R.L. Nussbaum and K.A. Phillips (2009) UCSF Center for Translational and Policy Research on Personalized Medicine. Clin Pharmacol Ther 86(1), 28-31. Walsh JM, Ladabaum U, Marshall D. Addressing the challenges of the clinical application of pharmacogenetic testing
73. K. Kim, S.O. Zakharkin and D.B. Allison (2010) Expectations, validity, and reality in gene expression profiling. J Clin Epidemiol 63 950-959.
74. C. Debouck and P.N. Goodfellow (1999) DNA microarrays in drug discovery and development. Nat Genet 21 48-50.
75. M.O. Hiltunen, M. Niemi and S. Ylä-Herttuala (1999) Functional genomics and DNA array techniques in atherosclerosis research. Curr Opin Lipidol 10 515-519.
76. K. Iwao-Koizumi, R. Matoba, N. Ueno, S.J. Kim, A. Ando, Y. Miyoshi, et al. (2005) Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23 422-431.
77. J.M. Street and J.W. Dear (2009) The application of mass-spectrometry-based protein biomarker discovery to theragnostics. Br J Clin Pharmacol 69 367-378.
78. G. Kim, L. Minig and E.C. Kohn (2009) Proteomic profiling in ovarian cancer. Intl J Gynecol Cancer 19 S2-S6.
79. N. Husseinzadeh (2011) Status of tumor markers in epithelial ovarian cancer: Has there been any progress? A review. Gynecol Oncol 120 152-157.
80. E.F. Petricoin III, A.M. Ardekani, B.A. Hitt, P.J. Leviine, V.A. Fusaro, S.M. Steinberg, et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 572-577.
81. D.F. Ransohoff (2005) Lessons from controversy: Ovarian cancer screening and proteomics. J Natl Cancer Inst 97 315-319.
82. F. Meani, S. Pecorelli, L. Liotta and E.F. Petricoin (2009) Clinical application of proteomics in ovarian cancer prevention and treatment. Mol Diag Ther 13 297-311.
83. K. Kim, I. Vishintin, A.B. Alvero and G. Mor (2009) Development and validation of a protein based signature for the detection of ovarian cancer. Clin Lab Med 29 47-55.
84. S. Braxton and T. Bedilion (1998) The integration of microarray information in the drug development process. Curr Opin Biotechnol 9 643-649.
85. A.J. Carlisle, V.V. Prabhu, A. Elkahloun, J. Hudson, J.M. Trent, W.M. Linehan, et al. (2000) Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol Carcinogen 28 12-22.
86. R.J. Jacob (2010) Bioinformatics for LC-MS/MS-based proteomics. Methods Mol Biol 658 61-91.